The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation

Dina Baier; Beatrix Schönhacker-Alte; Mate Rusz; Christine Pirker; Thomas Mohr; Theresa Mendrina; Dominik Kirchhofer; Samuel M. Meier-Menches; Katharina Hohenwallner; Martin Schaier; Evelyn Rampler; Gunda Koellensperger; Petra Heffeter; Bernhard Keppler; Walter Berger

doi:10.3390/pharmaceutics14020238

The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation

Dina Baier
, Beatrix Schönhacker-Alte
, Mate Rusz
, Christine Pirker
, Thomas Mohr
, Theresa Mendrina
, Dominik Kirchhofer
, Samuel M. Meier-Menches
, Katharina Hohenwallner
, Martin Schaier
, Evelyn Rampler
, Gunda Koellensperger
, Petra Heffeter
, Bernhard Keppler
, Walter Berger (Korresp. Autor*in)

Veröffentlichungen: Beitrag in Fachzeitschrift › Artikel › Peer Reviewed

Originalsprache	Englisch
Aufsatznummer	238
Seitenumfang	27
Fachzeitschrift	Pharmaceutics
Jahrgang	14
Ausgabenummer	2
DOIs	https://doi.org/10.3390/pharmaceutics14020238
Publikationsstatus	Veröffentlicht - 20 Jan. 2022

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

ÖFOS 2012

301209 Pharmazie
301206 Pharmakologie

Zugriff auf Dokument

10.3390/pharmaceutics14020238Lizenz: CC BY 4.0

https://phaidra.univie.ac.at/o:1660094Lizenz: CC BY 4.0

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Zitationsweisen

Baier, D., Schönhacker-Alte, B., Rusz, M., Pirker, C., Mohr, T., Mendrina, T., Kirchhofer, D., Meier-Menches, S. M., Hohenwallner, K., Schaier, M., Rampler, E., Koellensperger, G., Heffeter, P., Keppler, B., & Berger, W. (2022). The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. Pharmaceutics, 14(2), Artikel 238. https://doi.org/10.3390/pharmaceutics14020238

@article{f8607c70cdf8430698b856606f79cff0,

title = "The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation",

keywords = "BOLD-100, KP1339, ruthenium, chemotherapy resistance, 2-deoxy-d-glucose, glycolysis, ER stress, autophagy, lysosome, colon cancer, pancreatic cancer, CELL LUNG-CANCER, ENERGY-METABOLISM, PROSTATE-CANCER, 2-DEOXY-D-GLUCOSE, EXPRESSION, 2-DEOXYGLUCOSE, AUTOPHAGY, DRUG, SUPPRESSES, RESISTANCE, Lysosome, Autophagy, Colon cancer, 2-deoxy-D-glucose, Chemotherapy resistance, Ruthenium, BOLD-100/KP1339, Pancreatic cancer, Glycolysis",

author = "Dina Baier and Beatrix Sch{\"o}nhacker-Alte and Mate Rusz and Christine Pirker and Thomas Mohr and Theresa Mendrina and Dominik Kirchhofer and Meier-Menches, \{Samuel M.\} and Katharina Hohenwallner and Martin Schaier and Evelyn Rampler and Gunda Koellensperger and Petra Heffeter and Bernhard Keppler and Walter Berger",

note = "Accession Number: WOS:000764715400001 PubMed ID: 35213972",

year = "2022",

month = jan,

day = "20",

doi = "10.3390/pharmaceutics14020238",

language = "English",

volume = "14",

journal = "Pharmaceutics",

publisher = "MDPI AG",

number = "2",

}

Baier, D, Schönhacker-Alte, B, Rusz, M, Pirker, C, Mohr, T, Mendrina, T, Kirchhofer, D, Meier-Menches, SM, Hohenwallner, K, Schaier, M , Rampler, E , Koellensperger, G, Heffeter, P, Keppler, B & Berger, W 2022, 'The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation', Pharmaceutics, Jg. 14, Nr. 2, 238. https://doi.org/10.3390/pharmaceutics14020238

TY - JOUR

T1 - The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation

AU - Baier, Dina

AU - Schönhacker-Alte, Beatrix

AU - Rusz, Mate

AU - Pirker, Christine

AU - Mohr, Thomas

AU - Mendrina, Theresa

AU - Kirchhofer, Dominik

AU - Meier-Menches, Samuel M.

AU - Hohenwallner, Katharina

AU - Schaier, Martin

AU - Rampler, Evelyn

AU - Koellensperger, Gunda

AU - Heffeter, Petra

AU - Keppler, Bernhard

AU - Berger, Walter

N1 - Accession Number: WOS:000764715400001 PubMed ID: 35213972

PY - 2022/1/20

Y1 - 2022/1/20

KW - BOLD-100

KW - KP1339

KW - ruthenium

KW - chemotherapy resistance

KW - 2-deoxy-d-glucose

KW - glycolysis

KW - ER stress

KW - autophagy

KW - lysosome

KW - colon cancer

KW - pancreatic cancer

KW - CELL LUNG-CANCER

KW - ENERGY-METABOLISM

KW - PROSTATE-CANCER

KW - 2-DEOXY-D-GLUCOSE

KW - EXPRESSION

KW - 2-DEOXYGLUCOSE

KW - AUTOPHAGY

KW - DRUG

KW - SUPPRESSES

KW - RESISTANCE

KW - Lysosome

KW - Autophagy

KW - Colon cancer

KW - 2-deoxy-D-glucose

KW - Chemotherapy resistance

KW - Ruthenium

KW - BOLD-100/KP1339

KW - Pancreatic cancer

KW - Glycolysis

UR - https://www.scopus.com/pages/publications/85123109083

U2 - 10.3390/pharmaceutics14020238

DO - 10.3390/pharmaceutics14020238

M3 - Article

C2 - 35213972

VL - 14

JO - Pharmaceutics

JF - Pharmaceutics

IS - 2

M1 - 238

ER -

The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation

UN SDGs

ÖFOS 2012

Zugriff auf Dokument

Andere Dateien und Links

Fingerprint

Zitationsweisen